

DAFTAR PUSTAKA

1. International Agency of Research on Cancer. GLOBOCAN 2020 : estimated cancer incidence, mortality, and prevalence worldwide in 2020. [Diakses 11 Februari 2021]. Dari : <https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf>.
2. Ghoncheh M, Mahdavifar N, Darvishi E, Salehiniya H. Epidemiology, incidence and mortality of breast cancer in Asia. *Asian Pacific J Cancer Prev*. 2016;17:47–52.
3. World Health Organization. Cancer Country Profiles: Indonesia. *Cancer Ctry Profiles*. 2014;22–3.
4. Rumah Sakit Umum Pusat (RSUP) Dr.M.Djamil, 2018. Data Kunjungan pasien rawat jalan di RSUP Dr. M. Djamil Padang tahun 2014-2018 di Poliklinik Bedah Padang. Instansi Rekam Medik RSUP Dr. M. Djamil Padang.
5. Kaur G, Dufour JM. Cell lines: Valuable tools or useless artifacts. *Spermatogenesis*. 2012;2(1):1–5.
6. Dai X, Cheng H, Bai Z, Li J. Breast cancer cell line classification and Its relevance with breast tumor subtyping. *J Cancer*. 2017;8(16):3131–41.
7. McDonald ES, Clark AS, Tchou J, Zhang P, Freedman GM. Clinical diagnosis and management of breast cancer. *J Nucl Med*. 2016;57:9S-16S.
8. Hermann RM, Clausing B, Mayer J, Carl UM, Nitsche M. Late radiation sequelae as a consequence of breast-conserving therapy with cobalt irradiation aggravated by various risk factors. *BJR|case reports*. 2015;1(2):20150026.
9. D'Huyvetter M, Vos JD, Xavier C, Pruszynski M, Sterckx YGJ, Massa S, *et al*. ¹³¹I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment. *Clin Cancer Res*. 2017; Nov; 23(21): 6616–6628.
10. Yuan J, You X, Ni G, Wang T, Cavezza S, Pan X, *et al*. Iodine-125 labeled Australian frog tree host-defense peptides caerin 1.1 and 1.9 better inhibit human breast cancer cells growth than the unlabeled peptides. ¹²⁵I-caerin 1.9 may better be used for the treatment of breast cancer. *Hell J Nucl Med*. 2018; 21(2): 115-120.
11. Milligan R, Pieri A, Critchley A, Peace R, Lennard T, O'Donoghue JM, *et al*. Radioactive seed localization compared with wireguided localization of non-palpable breast carcinoma in breast conservation surgery-The first experience in the United Kingdom. *Br J Radiol*. 2018;91(1081).

12. Elliyanti A, Rusnita D, Afriani N, Susanto YDB, Susilo VY, Setiyowati S, *et al.* Analysis Natrium Iodide Symporter Expression in Breast Cancer Subtypes for Radioiodine Therapy Response. *Nucl Med Mol Imaging* (2010). 2020;54(1):35–42.
13. Wyszomirska A. Iodine-131 for therapy of thyroid diseases. Physical and biological basis. *Nucl Med Rev.* 2012;15(2):120–3.
14. Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S, *et al.* Cancer development, progression, and therapy: An epigenetic overview. *Int J Mol Sci.* 2013;14(10):21087–113.
15. Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. *Biol Res.* 2017;50(1):1–23.
16. Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, *et al.* Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes Dis.* 2018;5(2):77–106.
17. Tana L. Hubungan antara Faktor Reproduksi dengan Tumor Payudara Berdasarkan Pemeriksaan Sadanis, Riset Penyakit Tidak Menular 2016. *Bul Penelit Kesehat.* 2019;47(4):227–36.
18. Brewer HR, Jones MF, Schoemaker MJ. Family history and risk of breast cancer : an analysis accounting for family structure. *Breast Cancer Res Treat.* 2017;165:193-200.
19. American Cancer Society. Breast Cancer Risk and Prevention. *Cancer Org.* 2019;1–45.
20. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, *et al.* The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. *J Clin Oncol.* 2002;20(9):2310–8.
21. American Cancer Society. Breast Cancer Early Detection and Diagnosis. *Cancer Org.* 2019:1-62.
22. Jackman RJ, Burbank F, Parker SH, Evans WP, Lechner MC, Richardson TR, *et al.* Atypical ductal hyperplasia diagnosed at stereotactic breast biopsy: Improved reliability with 14-gauge, directional, vacuum-assisted biopsy. *Radiology.* 1997;204(2):485–8.

23. Susan Klein. Evaluation of Palpable Breast Masses. *Am Fam Physician*. 2005;71(9):1731–8.
24. Mitri Z, Constantine T, O'Regan R. The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. *Chemother Res Pract*. 2012;2012:1–7.
25. Gajria D, Chandarlapaty S. HER2-amplified breast cancer: Mechanisms of trastuzumab resistance and novel targeted therapies. *Expert Rev Anticancer Ther*. 2011;11(2):263–75.
26. Zaha DC. Significance of immunohistochemistry in breast cancer. *World J Clin Oncol*. 2014;5(3):382–92.
27. Jonat W, Arnold N. Is the Ki-67 labelling index ready for clinical use? *Ann Oncol*. 2011;22(3):500–2.
28. Breastcancer.org. Your Guide to the Breast Cancer Pathology Report. 2016. [Diakses: 27 November 2020]. Dari: https://www.breastcancer.org/symptoms/diagnosis/getting_path_report.
29. Schnitt SJ. Classification and prognosis of invasive breast cancer: From morphology to molecular taxonomy. *Mod Pathol*. 2010;23:60–4.
30. Rakha EA, Reis-filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, *et al*. Histological Grade Prognosis. *Breast Cancer Res*. 2010;12(207):1–12.
31. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/414/2018 Tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Payudara. [Diakses: 27 November 2020]. Dari: <http://kanker.kemkes.go.id/guidelines/PNPKPayudara.pdf>.
32. Zhou S, Shi W, Meng D. Interoperative radiotherapy of seventy-two cases of early breast cancer patients during breast-conserving surgery. *Asian Pac J Cancer Prev*. 2012;13:1131-5.
33. Wikipedia. Cell Culture. [Diakses 2 Desember 2020]. Dari: https://en.wikipedia.org/wiki/Cell_culture.
34. Comşa Ş, Cîmpean AM, Raica M. The story of MCF-7 breast cancer cell line: 40 Years of experience in research. *Anticancer Res*. 2015; 35(6):3147–54.
35. Wikipedia. SKBR3. [Diakses 2 Desember 2020]. Dari: <https://en.wikipedia.org/wiki/SKBR3>.

36. Kathryn JC, Sireesha V G, Stanley L. Triple Negative Breast Cancer Cell Lines: One Tool in the Search for Better Treatment of Triple Negative Breast Cancer. *Breast Dis.* 2012;32:35–48.
37. Commissariat à l'Énergie Atomique et aux Energies Alternatives. Radioactivity. 2005. [Diakses: 3 Desember 2020]. Dari: <https://www.cea.fr/english/Documents/thematic-publications/radioactivity.pdf>
38. Li Q, Tian Y, Yang D, Liang Y, Cheng X, Gai B. Permanent iodine-125 seed implantation for the treatment of nonresectable retroperitoneal malignant tumors. *Technol Cancer Res Treat.* 2019;18:1–8.
39. Irramah M, Kurniawati Y, Susilo V, Setiyowati S, Elliyanti A. Uptake and effect of radioiodine exposure on SKBR-3 cell lines. *Maj Kedokt Andalas.* 2019;43(1):23.
40. Riss TL, Moravec RA, Niles AL. Cytotoxicity Testing: Measuring Viable Cells, Dead Cells, and Detecting Mechanism of Cell Death. *Methods Mol Biol.* 2011;740: 103-114.
41. He Y, Zhu Q, Chen M, Huang Q, Wang W. The changing 50 % inhibitory concentration (IC 50) of cisplatin : a pilot study on the artifacts of the MTT assay and the precise measurement of density-dependent chemoresistance in ovarian cancer. *Oncotarget.* 2016;7(43).
42. Novatama SM, Kusumo E, Supartono. Identifikasi Betasianin dan Uji Antioksidan Ekstrak Buah Bit Merah (*Beta vulgaris* L). *Indo. J. Chem. Sci.* 2014;5(3):3-6.
43. Blois M. Antioxidant determinations by the use of a stable free radical. *Nature.* 1958;181(4617): 1199-1200.
44. Elliyanti A, Susilo VY, Setiyowati S, Ramli M, Masjhur JS, Achmad TH. Uptake and cytotoxicity characterization of radioiodine in MCF-7 and SKBR3 breast cancer cell lines. *Atom Indones.* 2016;42(3):145–9.
45. Kelkar MG, Senthilkumar K, Jadhav S, Gupta S, Ahn BC, De A. Enhancement of human sodium iodide symporter gene therapy for breast cancer by HDAC inhibitor mediated transcriptional modulation. *Sci Rep.* 2016;6:1–14.
46. Elliyanti A. Peran C-Fos Sebagai Agen Proliferasi Dan Pro-Apoptosis Sebagai Strategi Pengembangan Pengobatan Kanker. *Maj Kedokt Andalas.* 2016;39(2):73.